Phase 1b Dutch chemotherapy-free neoadjuvant trastuzumab + pertuzumab + tucatinib (triple HER2 blockade) in HER2+ early breast cancer. ~73% pCR signal — practice-questioning result.
Discover KOL Sentiment on TRAIN-4 →Design - Phase 1b Dutch (Netherlands Cancer Institute / BOOG) chemotherapy-free neoadjuvant triple HER2 blockade: trastuzumab + pertuzumab + tucatinib (plus endocrine therapy if HR+), HER2+ early breast cancer (NCT06162559).
pCR - Approximately 73% pathologic complete response overall - a practice-questioning chemotherapy-free signal.
Safety - Adding tucatinib to trastuzumab + pertuzumab introduces tucatinib-class toxicities - chiefly diarrhea and transaminase (AST/ALT) elevations - on top of the dual-blockade profile; described as manageable.
Strategy - Chemotherapy-free neoadjuvant de-escalation using triple HER2 blockade.
Regulatory - Investigational; not FDA approved. Component agents are individually approved in HER2+ breast cancer.
Sponsor / drugs - Netherlands Cancer Institute (BOOG); trastuzumab (Herceptin) + pertuzumab (Perjeta) + tucatinib (Tukysa).
Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Last updated July 21, 2026.
Trial slides shared by KOLs at ESMO Breast 2026 (#ESMOBreast26). Click any image to expand. OCR text extracted via AWS Textract.
[Slide 1] TRAIN-4 study design Single center, phase 1b study Primary endpoint All grade AEs (CTCAE V 5.0) AFTV 6x trastuzumab pertuzumab Stage II-IIIA 3x > 65% tucatinib + Al* Secondary endpoints Breast Cancer trastuzumab Response pCR (ypTO/is, NO) HER2 3+ pertuzumab Evaluation Surgery RCB tucatinib (MRI) rCR n = 30 Dose reductions + AI* AFTV 6x PTC-Ptz + Al* < 65% Dose interruptions Event-free survival Overall survival * Patients with endocrine-sensitive disease received concurrent Aromatase Inhibition (AI) + LHRHa if premenopausal FTV = Functional Tumor Volume (cubic millimeter with enhancement)¹² PTC-Ptz = paclitaxel, trastuzumab, carboplatin and pertuzumab Patient were enrolled between December 2023 and June 2025 MO ontent of this presentation is copyright and responsibility of Fleur Louis (f.louis@nki.nl). Permission is required for re-use Hviton Radiology 2016 Onishi Cancer Research 2022
[Slide 1] De-Escalating by Adding Oral TKIs 217RO TRAIN-4: Neoadjuvant Tucatinib + HP in HER2+ ESBC Louis et al Radiologic Response HER2 state Single center phase lb trial (n=30) É Heterogeneous 3+ Homogeneous 3+ Therapy determined by functional tumor volume (FTV) basella change FY 2 trom 50% switched to 67% premenopausal, 63% N-, 83% homogeneous HER2 3+; 50% HR+ neoad chemo d/c tucatinib 75% due AEs pCR: 73%, RCB 0+1`: 80% across ER receptor status Safety: 5 (17%) d/c tucatinib early due to AST elevation; 2 (7%) gr 3 diarrhea Patients 100% Primary endpoint 17% All grade AEs (CTCAE 5.0) 90% E AFTV 6x trastuzumab pertuzumab 10% 13% Stage II-IIA 3x >65% tucatinib Al* 7% Secondary endpoints É Breast Cancer trastuzumab Response pCR ypTOIs, NO) HER2 3+ pertuzumab Evaluation Surgery RCB $ RCB4 tucatinib (MRI) CR 50% RCB 30 Al* AFTV Dose reductions 6 *RCB4/PCR 6x PTC-Ptz Al* Dose interruptions 73% 73% <65% Event-free survival 30% Overall survival 20% 10% # 70% of patients never received chemotherapy Homane receptor-negative Homone receptor-positive* Median follow-up: 18.7 months (range 8.7 - 21.2) 19-month EFS rate: 100% (95% CI 100 - 100) Conclusions - remarkable efficacy! CS Scanned with Car eaily requies larger confirmation and balancing types of toxicity with efficacy Diarrhea and liver enzyme elevation but no alopecia or neuropathy Content of this presentation is copyright and responsibility of the author Identifying qualifying high responders is critical ESMO
[Slide 1] KOL Pulse / Conference Intelligence ESMO Breast 2026 Live Coverage Berlin, Germany . May 6 - 8, 2026 256 Tweets . 57 KOLs . 46.6K Impressions KOL Social Media Perspectives Top Discussion Leaders
Highest-engagement tweets about this trial, ranked by KOL discussant count (replies + quote-tweets). Replies in green, quote-tweets in blue. Wall Street, stock-promo, and non-substantive replies excluded.
Other excitement in "right sizing" is adding➕ tucatinib and taking away➖ chemo in neoadj #HER2 #bcsm ....#TRAIN4 HP + tucatinib neoadjuvant 93% were able to omit chemo based on response pCR 73% without cytotoxic here! 👏 #ESMOBreast26 @hoperugo https://t.co/uUZOgcsOf1
TRAIN-4 is a single-centre, non-randomized Phase 1b study from the Netherlands Cancer Institute evaluating neoadjuvant chemotherapy-free dual HER2 blockade plus tucatinib in Stage II–IIIA HER2-positive early breast cancer. Building on PHERGain's PET-adapted strategy, TRAIN-4 adds tucatinib to trastuzumab + pertuzumab and uses DCE-MRI functional tumour volume (FTV) decrease ≥65% to identify deep responders who continue chemo-free. Reported at ESMO Breast 2026 with high pCR rates (~73%) supporting the chemo-free approach in selected patients.
Population: Stage II–IIIA HER2+ primary breast cancer (cT2-3 ≥2 cm and/or cN1-2 confirmed). HER2 IHC 3+ on pre-treatment biopsy. WHO PS 0-1, age ≥18, LVEF ≥50%. Both ER+ (with concurrent AI ± LHRH agonist) and ER- enrolled.
Interventions: Neoadjuvant trastuzumab + pertuzumab + tucatinib × 3 cycles → DCE-MRI assessment → responders: continue T+P+tucatinib × 6 cycles; non-responders: switch to paclitaxel + carboplatin + T+P × 6 cycles.
Endpoints: Primary: pCR rate (ypT0/is, N0) overall and in chemo-free arm. Secondary: radiologic CR on DCE-MRI, safety, ctDNA monitoring (translational).
TRAIN-4 reports a 73% pCR rate in chemo-free deep-responders identified by DCE-MRI FTV decrease ≥65% after 3 cycles of T+P+tucatinib. The study supports adding tucatinib to dual HER2 blockade as a way to further increase the proportion of HER2+ EBC patients who can avoid neoadjuvant chemotherapy. Combined with PHERGain (PET-adapted) and PHERGain-2 (pCR-guided), TRAIN-4 contributes to a growing portfolio of chemo-free strategies for HER2+ early disease.
Adding tucatinib to trastuzumab + pertuzumab introduces tucatinib-class toxicities — most notably diarrhoea and transaminase (AST/ALT) elevations — on top of the HP dual-blockade profile. These are distinct from the typical HP-alone profile. CNS-favourable activity of tucatinib (established in HER2CLIMB) is a key rationale for evaluating this combination in early-stage disease where occult micrometastases are a concern.
Erika Hamilton flagged TRAIN-4 as part of a HER2+ “right sizing” trend: “adding tucatinib and taking away chemo in neoadj #HER2” in a Phase 1b that produced “HP + tucatinib neoadjuvant” results in which “93% were able to omit chemo based on response” and “pCR 73% without cytotoxic here.” The OCR-captured slide from presenter F.M. Louis flagged the trade-off directly — 17% of patients switched to neoadjuvant chemo, “5 (17%) d/c tucatinib early due to AST elevation,” and “2 (7%) gr 3 diarrhea” — and stated “Identifying qualifying high responders is critical.” Few independent KOL voices weighed in on TRAIN-4 specifically beyond Hamilton; the conversation remains thin pending larger confirmatory data.
TRAIN-4 (NCT06162559) is a Dutch (Netherlands Cancer Institute / BOOG) Phase 1b chemotherapy-free neoadjuvant strategy trial testing triple HER2 blockade - trastuzumab plus pertuzumab plus tucatinib, with endocrine therapy added for hormone-receptor-positive disease - in HER2-positive early breast cancer.
TRAIN-4 reported an approximately 73% pathologic complete response rate with the chemotherapy-free triple HER2-blockade strategy, a result the investigators framed as practice-questioning because it suggests a subset of HER2-positive early breast cancer patients might achieve high response without chemotherapy. Confirmatory, larger studies would be required before changing practice.
No. The TRAIN-4 chemotherapy-free triple HER2-blockade neoadjuvant regimen is investigational and not FDA approved. Its component drugs - trastuzumab, pertuzumab and tucatinib - are each individually FDA-approved in HER2-positive breast cancer, but not in this specific chemotherapy-free neoadjuvant combination.
Adding tucatinib to the trastuzumab-plus-pertuzumab backbone introduces tucatinib-class toxicities, most notably diarrhea and elevations in liver transaminases (AST/ALT), on top of the dual-blockade profile. These were described as manageable but distinguish the triple-blockade regimen from dual HER2 blockade alone.
ClinicalTrials.gov records TRAIN-4 (NCT06162559) as a Phase 1 (Phase 1b) study run by the Netherlands Cancer Institute. Some page elements label it 'Phase II'; the ClinicalTrials.gov registration is the authoritative source and lists it as Phase 1b.
| Handle | Name | Sentiment | Tweet (excerpt) | Imp. |
|---|---|---|---|---|
| @Dr_ElvinaA | Elvina Almuradova | Neutral | TRAIN-4 redefines the neoadjuvant landscape in HER2+ early #BreastCancer. A chemotherapy-free combination of Tucatinib +… | 555 |
| @ErikaHamilton9 | Erika Hamilton, MD, FASCO | Neutral | Other excitement in "right sizing" is adding➕ tucatinib and taking away➖ chemo in neoadj #HER2 #bcsm ....#TRAIN4 HP + … | 265 |
| @KolPulseAI | KOL Pulse AI | Neutral | KOL Updates #ESMOBreast26 Day 2 — Berlin 🔥 TRAIN-4: 73% pCR chemo-free HER2+ neoadj 🔥 PHERGain-2 published in Annals of … | 210 |
| @PreetamJainOnco | Dr Preetam Jain | Neutral | TRAIN-4: Tucatinib-Based Neoadjuvant Regimen Achieves High pCR Without Chemotherapy in HER2+ Early Breast Cancer https:/… | 99 |
